Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Minocycline - Dr Reddys Laboratories/Journey Medical Corporation

Next Previous
Drug Profile

Minocycline - Dr Reddys Laboratories/Journey Medical Corporation

Alternative Names: DFD 10; DFD-29; Emrosi; Minocycline HCl extended release - Dr. Reddy's Laboratories/Promius Pharma/Journey Medical Corporation; Minocycline hydrochloride extended release - Dr Reddy's Laboratories; Minocycline modified release capsules - Dr Reddy's Laboratories; MINOLIRA

Latest Information Update: 28 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dr Reddys Laboratories
  • Developer Dr Reddys Laboratories; Journey Medical Corporation; Promius Pharma
  • Class Amides; Anti-inflammatories; Antiacnes; Antibacterials; Dimethylamines; Eye disorder therapies; Neuroprotectants; Skin disorder therapies; Small molecules; Tetracyclines
  • Mechanism of Action Glial cell inhibitors; Interleukin 1 alpha inhibitors; Interleukin 6 modulators; Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acne vulgaris; Rosacea

Most Recent Events

  • 28 Jun 2025 No recent reports of development identified for phase-I development in Acne-vulgaris(In volunteers) in Canada (PO, Controlled release)
  • 31 Mar 2025 Launched for Rosacea in USA (PO)
  • 12 Nov 2024 Journey Medical Corporation intends to launch minocycline for Rosacea in late Q1 or early Q2 of 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top